Oct 28, 2025 7:34 AM Eastern Daylight Time Alto Neuroscience to Participate in Upcoming Investor Conferences Share MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Alto Neuroscience, Inc. ("Alto†) (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that members of the Company's management team will present at the following upcoming investor conferences: Available presentations will be accessible via a live w ...

Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the "long context," investors will essentially be "buying high, but hoping to sell even higher." And for investors following this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving in that direction. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.Whil ...

Shares of Alto Neuroscience, Inc. (ANRO) have gained 162.9% over the past four weeks to close the last trading session at $10.2, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $13 indicates a potential upside of 27.5%.The mean estimate comprises seven short-term price targets with a standard deviation of $2.45. While the lowest estimate of $10.00 indicates a 2% decline from the ...

MOUNTAIN VIEW, Calif .-- (BUSINESS WIRE) ---- $anro #cns--Alto Neuroscience, Inc. ("Alto†) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, announced today that it has entered into a securities purchase agreement with institutional and accredited investors to sell securities in a private placement financing (the "PIPE†) for gross proceeds of approximately $50 million, before deducting offering expenses. The f ...

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $anro #cns--Alto Neuroscience, Inc. ("Alto†) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, announced today that, following a successful outcome from a recent FDA meeting, it plans to accelerate the development of ALTO-207 for people with treatment resistant depression (TRD). The $50 million private placement announced today supports expanded development of ALTO-207, ...

事件概述 - 律师事务所Bragar Eagel & Squire, P C正在对Alto Neuroscience Inc (NYSE: ANRO) 展开调查，涉及该公司董事会可能违反其对公司的 fiduciary duties [1] - 调查源于一项针对Alto的集体诉讼，该诉讼于2025年7月21日提交，类别期间为2024年2月2日至2024年10月22日 [1] 指控内容 - 指控称，支持IPO的发行文件存在疏忽准备的问题 [6] - 在类别期间内，被告未能披露ALTO-100在治疗重度抑郁症(MDD)方面的效果不如其向投资者所宣称的那样有效 [6] - 因此，ALTO-100的临床、监管和商业前景被夸大，进而导致Alto的业务和/或财务前景被夸大 [6] 股价影响 - 2024年10月22日，Alto发布新闻稿公布了ALTO-100治疗MDD的2b期试验顶线结果，显示其未达到主要终点 [6] - 此消息导致Alto股价在2024年10月23日下跌每股10.17美元，跌幅达69.99%，收盘报每股4.36美元 [6]

法律调查启动 - Johnson Fistel律所正在调查Alto Neuroscience公司高管和董事可能违反信托义务的行为 [1] 诉讼核心指控 - 联邦证券欺诈集体诉讼指控公司高管就公司业务、运营和前景做出重大虚假和误导性陈述 [2] - 具体指控涉及主要产品ALTO-100治疗重度抑郁症的疗效低于公司向投资者传达的水平 [2] - 指控称ALTO-100的临床、监管和商业前景被夸大，导致公司业务和财务前景亦被夸大 [2] - 因此，公司在相关时间内的公开声明存在重大虚假和误导性 [2] 股东潜在行动 - 股东可能能够推动公司治理实践改革，并为公司追回资金 [3] - 股东可寻求法院批准的激励性奖励，且无需个人承担费用 [3]

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $ANRO #FastTrack--Alto Neuroscience, Inc. ("Alto†) (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ALTO-101 for the treatment of cognitive impairment associated with schizophrenia (CIAS). There are currently no approved treatments for CIAS, a core feature of schizophr ...

集体诉讼事件 - 集体诉讼代表在2024年2月2日左右公司首次公开募股中根据发售文件购买或收购Alto Neuroscience Inc普通股的投资者 [1] - 集体诉讼也涵盖在2024年2月2日至2024年10月22日期间购买或收购Alto证券的投资者 [1] - 诉讼涉及纽约证券交易所代码为ANRO的Alto Neuroscience Inc公司 [1]

NEW YORK, Sept. 19, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Alto Neuroscience, Inc. (NYSE: ANRO): (i) pursuant and/or traceable to Alto’s initial public offering conducted on or about February 2, 2024 (the “IPO”); and/or (ii) securities between February 2, 2024 and October 22, 2024, both dates inclusive (the “Class Period”), of the important September 19, 2025 lead plaintiff deadline. SO WHAT: If you purchased Alto securities yo ...